2cureX is accelerating the commercialization of IndiTreat® by signing two distributor agreements to prepare for launch in second half of 2020

March 6 | 2020
2cureX AB (“2cureX”, NASDAQ: 2CUREX) today announces that the company has established two partnership agreements to support the commercialization of the IndiTreat® test in Europe. The partnership agreements with YourRad AB, Sweden and Paralax Life Science Group, Bulgaria will help increase the commercial activities and interactions with public and private hospitals in these markets.

2cureX will launch the IndiTreat® test in the European market in the second half of 2020.

These distributor partnerships will help position IndiTreat® towards a larger customer base and will utilize our distributor’s knowledge and network within the oncology field in the Nordic and Eastern European markets. Besides engagement in the preparation for launch, the collaboration with the new partners will support 2cureX’s commitment to bring the IndiTreat® test into the hands of customers as part of the Early Access initiative (Pre-Launch).

“Partnering with YourRad AB in Sweden and Paralax Life Science Group in Bulgaria will pose a great opportunity to broaden our exposure to customers and access to their specific networks within Cancer care in these markets” says Maarten van der Linden, Chief Business Officer and he continues; “I’m excited to start these collaborations, confirming that we are making important progress in our commercial strategy”.

”The products of 2cureX will reshape the decision making in cancer treatment in Bulgaria and probably later in other countries in the region”, says Dr. Dimitar Georgiev, CEO of Paralax Life Science, Bulgaria and he continues; “It is a breakthrough technology that offers a truly individualized treatment approach”.

 “We really support the concept of functional Precision Medicine and we’re very excited to join 2cureX on this journey to make IndiTreat® available for clinicians and cancer patients in the Nordic market”, says Magnus Forss, Managing Director of YourRad AB, Sweden.

IndiTreat® capitalizes on a clear market need to go beyond classical genomic testing when tailoring cancer treatment for the individual patient. The IndiTreat test can fill this void by providing functional information of how available drug treatments directly influence the patient’s tumor. The IndiTreat® test identifies the drug treatment to which the individual patient is sensitive, and just as important, to which treatment the patient is resistant.

For more information about 2cureX:

Ole Thastrup, Chief Executive Officer
E-mail: ot@2curex.com
Telephone: +45 2211 5399

Certified Adviser

Svensk Kapitalmarknadsgranskning AB
Email: ca@skmg.se
Phone: +46 11 32 30 732

This information is information that 2cureX AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on March 6, 2020.


About 2cureX

2cureX has developed the IndiTreat® (Individual Treatment) test. IndiTreat® establishes thousands of 3D micro-tumours that are similar to the patient’s tumour and identifies the treatment that most effectively kills the patient’s tumor. Immediately after the test, the patient can be offered the selected treatment.

IndiTreat® is being clinically validated in clinical studies in colorectal cancer, ovarian cancer, pancreatic cancer and preventive cancer medicine. The clinical programs are conducted at major cancer hospitals in Denmark, Germany and United Kingdom.

IndiTreat® is presently being introduced into the European market through an Early Access Program. 

The aspiration is that IndiTreat® becomes a standard tool in Precision Medicine for cancer patients.

The company is listed at the Nasdaq First North Growth Market in Stockholm (symbol “2CUREX”).